Defence Receives No Objection Letter from Health Canada for Phase I Trial of Its Accum-002 (Accutox) as an Anti-cancer Molecule in Patients with Melanoma

By
Emily Salmini
-
0
82
Defence Therapeutics, Inc. announced that it received a No Objection Letter from Health Canada for its Clinical Trial Study number ACCUM-002-01.
[Defence Therapeutics, Inc.]
Press Release